Short Interest in AlloVir, Inc. (NASDAQ:ALVR) Decreases By 19.2%

AlloVir, Inc. (NASDAQ:ALVR) was the recipient of a large decline in short interest in the month of October. As of October 31st, there was short interest totalling 3,950,000 shares, a decline of 19.2% from the October 15th total of 4,890,000 shares. Based on an average daily trading volume, of 256,400 shares, the short-interest ratio is currently 15.4 days.

AlloVir Price Performance

Shares of ALVR stock opened at $0.57 on Friday. The company’s fifty day moving average price is $0.79 and its two-hundred day moving average price is $0.77. The firm has a market capitalization of $65.74 million, a P/E ratio of -0.65 and a beta of 0.75. AlloVir has a 12 month low of $0.53 and a 12 month high of $2.49.

AlloVir (NASDAQ:ALVR) last released its quarterly earnings results on Tuesday, November 12th. The company reported ($0.04) EPS for the quarter, topping the consensus estimate of ($0.14) by $0.10.

Hedge Funds Weigh In On AlloVir

Institutional investors have recently made changes to their positions in the business. Cubist Systematic Strategies LLC increased its stake in shares of AlloVir by 152.3% in the second quarter. Cubist Systematic Strategies LLC now owns 49,816 shares of the company’s stock worth $36,000 after buying an additional 30,072 shares during the last quarter. Price T Rowe Associates Inc. MD raised its stake in AlloVir by 127.4% during the first quarter. Price T Rowe Associates Inc. MD now owns 97,986 shares of the company’s stock valued at $74,000 after buying an additional 54,900 shares in the last quarter. Point72 Asia Singapore Pte. Ltd. bought a new position in AlloVir during the 2nd quarter worth approximately $55,000. Finally, Acadian Asset Management LLC grew its position in shares of AlloVir by 694.6% in the 1st quarter. Acadian Asset Management LLC now owns 1,587,451 shares of the company’s stock worth $1,197,000 after acquiring an additional 1,387,666 shares in the last quarter. 66.05% of the stock is owned by institutional investors and hedge funds.

AlloVir Company Profile

Allovir, Inc, a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company's lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus.